Your browser is no longer supported. Please, upgrade your browser.
KRYS Krystal Biotech, Inc. daily Stock Chart
Krystal Biotech, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own19.20% Shs Outstand17.36M Perf Week-3.67%
Market Cap816.64M Forward P/E- EPS next Y-2.93 Insider Trans-4.06% Shs Float14.19M Perf Month-10.81%
Income-20.30M PEG- EPS next Q-0.47 Inst Own60.10% Short Float11.16% Perf Quarter-13.26%
Sales- P/S- EPS this Y-23.50% Inst Trans0.46% Short Ratio7.89 Perf Half Y-15.08%
Book/sh11.43 P/B3.51 EPS next Y-34.40% ROA-9.80% Target Price- Perf Year-15.82%
Cash/sh9.17 P/C4.37 EPS next 5Y- ROE-10.10% 52W Range31.89 - 66.85 Perf YTD-27.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.00% Beta-
Dividend %- Quick Ratio46.40 Sales past 5Y- Gross Margin- 52W Low25.78% ATR2.80
Employees52 Current Ratio46.40 Sales Q/Q- Oper. Margin- RSI (14)38.61 Volatility6.03% 6.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.90% Profit Margin- Rel Volume0.67 Prev Close37.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume200.71K Price40.11
Recom1.80 SMA20-7.88% SMA50-17.35% SMA200-18.67% Volume134,720 Change6.22%
Jun-04-20Initiated Evercore ISI Outperform $90
Sep-24-19Initiated Goldman Neutral $60
Aug-06-19Reiterated H.C. Wainwright Buy $56 → $59
Jun-24-19Reiterated H.C. Wainwright Buy $38 → $56
Jun-24-19Reiterated Chardan Capital Markets Buy $57.50 → $75
May-30-19Initiated Guggenheim Buy
Sep-11-18Initiated Cantor Fitzgerald Overweight $28
Jun-26-20 11:20AM  
Jun-08-20 04:01PM  
May-25-20 10:00AM  
May-19-20 06:53PM  
May-18-20 09:57PM  
May-14-20 08:00AM  
May-04-20 08:00AM  
Apr-21-20 08:05AM  
Apr-01-20 08:24AM  
Mar-10-20 08:00AM  
Feb-25-20 08:21AM  
Feb-21-20 08:00AM  
Jan-24-20 08:00AM  
Jan-21-20 08:00AM  
Jan-02-20 12:28PM  
Dec-23-19 12:00PM  
Dec-14-19 09:42PM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-03-19 08:50AM  
Nov-26-19 08:00AM  
Nov-14-19 10:00AM  
Nov-04-19 08:00AM  
Oct-30-19 05:23PM  
Oct-29-19 08:00AM  
Oct-10-19 08:00AM  
Oct-04-19 08:38AM  
Sep-30-19 08:00AM  
Sep-27-19 08:00AM  
Sep-04-19 08:00AM  
Aug-27-19 04:05PM  
Aug-14-19 03:12PM  
Aug-05-19 08:00AM  
Jul-01-19 09:05AM  
Jun-27-19 11:18AM  
Jun-25-19 01:15PM  
Jun-24-19 04:31PM  
Jun-14-19 08:00AM  
May-15-19 08:00AM  
May-06-19 08:00AM  
Apr-29-19 08:00AM  
Mar-29-19 08:00AM  
Mar-12-19 08:00AM  
Mar-07-19 08:58AM  
Mar-06-19 08:00AM  
Mar-04-19 08:00AM  
Mar-01-19 08:00AM  
Feb-22-19 08:00AM  
Jan-18-19 01:57PM  
Jan-15-19 08:00AM  
Dec-19-18 08:00AM  
Nov-21-18 07:55AM  
Nov-20-18 08:00AM  
Nov-05-18 08:00AM  
Oct-23-18 04:01PM  
Oct-22-18 07:15PM  
Oct-18-18 06:03PM  
Oct-17-18 04:01PM  
Oct-15-18 07:45AM  
Oct-04-18 04:05PM  
Oct-01-18 08:00AM  
Sep-25-18 08:00AM  
Aug-29-18 04:05PM  
Aug-23-18 08:00AM  
Aug-17-18 12:31PM  
Aug-16-18 07:17PM  
Aug-09-18 08:00AM  
Aug-06-18 08:00AM  
Jul-16-18 08:00AM  
Jul-13-18 10:05AM  
Jun-08-18 05:29AM  
May-29-18 07:00AM  
May-24-18 08:00AM  
May-10-18 09:18AM  
May-09-18 08:00AM  
May-07-18 08:00AM  
Apr-26-18 08:00AM  
Apr-23-18 07:00AM  
Apr-19-18 08:00AM  
Apr-18-18 04:01PM  
Mar-27-18 08:00AM  
Mar-12-18 08:00AM  
Mar-05-18 08:00AM  
Jan-16-18 08:00AM  
Oct-20-17 02:16PM  
Sep-25-17 08:15PM  
Sep-24-17 09:57AM  
Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krishnan SumaChief Operating OfficerJun 15Sale43.5050,0002,174,7751,886,064Jun 17 04:14 PM
Krishnan Krish SPresident and CEOMay 18Sale57.8823,1611,340,5211,886,462May 19 05:01 PM
Krishnan Krish SPresident and CEOMay 15Sale58.3626,8391,566,3861,909,623May 19 05:01 PM
Krishnan SumaChief Operating OfficerMar 18Sale40.2065926,4931,936,064Mar 18 08:14 PM
Krishnan SumaChief Operating OfficerMar 17Sale40.5812,180494,2051,936,723Mar 18 08:14 PM
Krishnan SumaChief Operating OfficerMar 16Sale40.142,559102,7141,948,903Mar 18 08:14 PM
Krishnan Krish SPresident and CEOFeb 20Sale60.9918,6811,139,3671,936,462Feb 20 05:27 PM
Krishnan Krish SPresident and CEOFeb 19Sale62.7618,6501,170,4631,955,143Feb 20 05:27 PM
Krishnan Krish SPresident and CEOFeb 18Sale62.6012,669793,0661,973,793Feb 20 05:27 PM
Krishnan SumaChief Operating OfficerDec 18Sale61.849,112563,4801,951,462Dec 18 05:56 PM
Krishnan SumaChief Operating OfficerDec 17Sale60.5319,9411,207,0251,960,574Dec 18 05:56 PM
Krishnan SumaChief Operating OfficerDec 16Sale63.5620,9471,331,4491,980,515Dec 18 05:56 PM
Riley Antony AChief Financial OfficerNov 19Option Exercise9.856,25061,5639,050Nov 21 04:05 PM
Krishnan Krish SPresident and CEONov 18Sale52.3322,1211,157,6021,986,462Nov 19 04:03 PM
Krishnan Krish SPresident and CEONov 15Sale50.4127,8791,405,2862,008,583Nov 19 04:03 PM